血清游离κ轻链与多发性骨髓瘤风险分层及克隆演化的初步研究
该回顾性研究纳入113例新诊断多发性骨髓瘤患者,分析血清游离κ、λ轻链及κ/λ比值与临床特征、细胞遗传学异常、预后及VRd方案疗效的关联。结果显示异常sFLC κ提示不良预后,且将sFLC κ纳入改良R-ISS模型可改善风险区分度。
要点
- 异常血清游离κ轻链提示新诊断骨髓瘤患者预后不良。
- 肾功能正常患者中,异常sFLC κ与高肿瘤负荷及VRd诱导后深缓解率低相关。
- 纳入sFLC κ的MR-ISS模型风险区分优于R-ISS。
核心结论
- 异常血清游离κ轻链是新诊断多发性骨髓瘤不良预后及VRd治疗反应欠佳的潜在标志物。
- 将sFLC κ整合入R-ISS形成的MR-ISS模型可改善风险分层。
研究设计与样本
- 回顾性分析113例新诊断多发性骨髓瘤患者,按肾功能分层。
- 收集基线临床数据、细胞遗传学标志(RB1/D13S319/IGH/1q21/P53/1p32)及治疗反应。
- 采用免疫组化评估肿瘤增殖、凋亡与血管生成,用Kaplan-Meier和Cox回归分析预后因素,并建立MR-ISS模型进行时间外部验证。
主要发现
- 异常sFLC κ提示不良预后。
- 肾功能正常患者中,异常sFLC κ与不良临床特征、高肿瘤负荷、抗凋亡及促血管生成的肿瘤微环境、D13S319缺失及VRd诱导后深缓解率低显著相关。
- MR-ISS模型风险区分优于R-ISS。
关键数值与推荐
- 异常sFLC κ与D13S319缺失及VRd诱导后较低深缓解率相关。
- MR-ISS模型在风险区分上优于R-ISS。
临床怎么用
- 对新诊断骨髓瘤患者可关注血清游离κ轻链水平以辅助预后判断。
- 可考虑将sFLC κ纳入R-ISS形成MR-ISS以优化风险分层。
局限性
- 回顾性研究,样本量113例。
- 单中心数据,需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy whose progression and relapse are influenced by clonal heterogeneity. Although serum free light chains (sFLCs) are key biomarkers for tumour burden assessment, the clinical value of λ, κ and their ratio remains controversial. This study investigated the associations of sFLC κ, λ and the κ/λ ratio with clinical features, cytogenetic abnormalities, prognosis and response to the VRd regimen (bortezomib, lenalidomide, dexamethasone) in newly diagnosed MM (NDMM) patients, aiming to optimize risk stratification. A retrospective analysis of 113 NDMM patients was conducted. Baseline clinical data, cytogenetic markers (RB1/D13S319/IGH/1q21/P53/1p32) and treatment responses were collected, with stratification by renal function. Tumour proliferation, apoptosis and angiogenesis were assessed by immunohistochemistry. Prognostic factors were evaluated using Kaplan-Meier and Cox regression analyses. A modified revised International Staging System (R-ISS) (MR-ISS) model incorporating sFLC κ was then developed and temporally externally validated. Abnormal sFLC κ indicated poor prognosis. Among NDMM patients with normal renal function, abnormal sFLC κ was significantly associated with adverse clinical features, high tumour burden, an anti-apoptotic and angiogenic tumour microenvironment, D13S319 deletion and a lower rate of deep remission after VRd induction. Moreover, the MR-ISS model demonstrated superior risk discrimination compared with the R-ISS. In conclusion, abnormal sFLC κ is a potential marker of poor prognosis and suboptimal response to VRd therapy in NDMM. Integrating sFLC κ with the R-ISS improves risk stratification, providing new evidence for clinical application of this biomarker.
引用
- Yang C, Xiao J, Zhao N, et al. Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma. Br J Haematol. 2026. PMID: 42108956. doi:10.1111/bjh.70541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。